Peripheral oedema in patients taking olanzapine

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Premarketing olanzapine trials indicated a 3% incidence of peripheral edema.
• Peripheral edema is a potential adverse effect of olanzapine, an atypical antipsychotic medication.

Purpose of the Study:

• To evaluate the incidence and characteristics of peripheral edema in outpatients actively treated with olanzapine.
• To identify potential risk factors associated with olanzapine-induced peripheral edema.

Main Methods:

• Observational study of 49 outpatients receiving active olanzapine treatment.
• Assessment of peripheral edema presence and severity.
• Analysis of demographic data, treatment duration/dosage, comorbidities, and concomitant medications.

Main Results:

• Peripheral edema was observed in 57% of subjects, with 10.2% experiencing severe edema.
• No significant differences were found based on gender, olanzapine dose/duration, comorbidities, or other psychotropic medications.
• A trend towards older age (P < 0.10) and increased thyroid abnormalities was noted in patients with edema.
• A positive correlation between age and edema severity was identified (P < 0.05).

Conclusions:

• The observed incidence of peripheral edema in this study (57%) is significantly higher than premarketing trial data (3%).
• Findings suggest that certain patient populations may be more vulnerable to developing peripheral edema as a side effect of olanzapine.
• Age and thyroid abnormalities appear to be potential contributing factors to olanzapine-induced peripheral edema.